Zacks Investment Research on MSN8d
IMVT Unlikely to Pursue Batoclimab for MG & CIDP Despite SuccessImmunovant IMVT announced top-line data from a late-stage study of its investigational candidate, batoclimab, for myasthenia ...
Immunovant, Inc. had positive results for batoclimab in trials for Myasthenia Gravis & CIDP; Thyroid Eye Disease data ...
Clinical Trials Arena on MSN8d
Immunovant will not seek approval for MG therapy, despite hitting endpointsThe company plans to use results from its Phase III myasthenia gravis study to support its pipeline candidate IMVT-1402 over ...
Switching to IMVT-1402 extends the head starts Immunovant has already ceded to its rivals. Argenx won FDA approval for ...
Immunovant, Inc. (NASDAQ:IMVT) released topline results from its Phase 3 study of batoclimab in myasthenia gravis (MG) and ...
The companies reported Wednesday that batoclimab showed improvements in myasthenia gravis patients in a Phase 3 trial.
Analysts were happy with batoclimab’s performance in the chronic autoimmune disorder, but Immunovant said it will continue to ...
Immunovant (IMVT) reported topline results from its Phase 3 study of batoclimab in MG and initial results from Period 1 of its Phase 2b study ...
Batoclimab, subcutaneous formulation, offers the potential for at-home administration, improving patient convenience and ...
Beyond the results in MG and CIDP, we believe that our core thesis - that deeper IgG reduction, at the levels achieved by high dose batoclimab and high dose IMVT-1402, leads to improved clinical ...
Immunovant IMVT announced top-line data from a late-stage study of its investigational candidate, batoclimab, for myasthenia gravis (MG) and initial results from Period 1 of a mid-stage study of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback